Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Conditions
Interventions
Maribavir
Ganciclovir
+3 more
Locations
134
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Arizona
Tucson, Arizona, United States
City of Hope National Medical Center
Duarte, California, United States
University of Southern California
Los Angeles, California, United States
UCLA Medical Center
Los Angeles, California, United States
UC Davis Medical Center
Sacramento, California, United States
Start Date
December 22, 2016
Primary Completion Date
August 17, 2020
Completion Date
August 17, 2020
Last Updated
November 3, 2021
NCT06439342
NCT06793124
NCT07488481
NCT06615921
NCT01877655
NCT03486834
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions